Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | ADRB2 | P07550 | 7/20 | 0.67 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.67 |
| ▸ | HTR1A | P08908 | 2/20 | 0.65 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.65 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.65 |
| ▸ | MAOA | P21397 | 1/20 | 0.65 |
| ▸ | HTR2B | P41595 | 1/20 | 0.65 |
| ▸ | CASR | P41180 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | DRD1 | P21728 | 1/20 | 0.61 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22640075 | 1.00 | MAPT (0.68) | MAPTADRB2ADRB1HTR1AADRA2A | |
| SCHEMBL11870445 | 0.89 | MAPT (0.78) | MAPTADRB2ADRB1HTR1AADRA2A | |
| Hydrochloric Acid SCHEMBL11870616 | 0.88 | MAPT (0.81) | MAPTADRB2ADRB1HTR1AADRA2A | |
| SCHEMBL10807838 | 0.86 | CASR (0.66) | MAPTADRB2ADRB1HTR1AADRA2A | |
| Cloranolol SCHEMBL80493 | 0.83 | SLC2A1 (0.62) | MAPTADRB2ADRB1HTR1AADRA2A | |
| Cloranolol SCHEMBL80494 | 0.83 | SLC2A1 (0.62) | MAPTADRB2ADRB1HTR1AADRA2A | |
| SCHEMBL10774981 | 0.82 | MAPT (0.68) | MAPTADRB2ADRB1HTR1AADRA2A | |
| SCHEMBL10595597 | 0.82 | MAPT (0.68) | MAPTADRB2ADRB1HTR1AADRA2A | |
| Pargolol SCHEMBL1254705 | 0.82 | MAPT (0.67) | MAPTADRB2ADRB1HTR1AADRA2A | |
| Cloranolol SCHEMBL1230788 | 0.82 | KMT2A (0.63) | MAPTADRB2ADRB1HTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10828281-B2 | Non-hydrophobic compounds for use in treating metastasis and/or cartilage defect | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2020-11-10 | — | — | US | disclosed |
| US-4391980-A | FOR INVERSION OF CONFIGURATION OF OPTICALLY ACTIVE COMPOUNDS | CIBA-GEIGY CORPORATION (US) | 1983-07-05 | — | — | US | disclosed |
| US-4294966-A | SALT FORMATION | CIBA-GEIGY CORPORATION (US) | 1981-10-13 | — | — | US | disclosed |
| EP-0007605-A1 | A process for inverting the configuration in optically active compounds and optically active intermediate compounds and their salts required therefor | CIBA-GEIGY AG (CH) | 1980-02-06 | — | — | EP | disclosed |
| US-4161530-A | CYCLIC SUBSTITUTED AMINO ALCOHOL BETA-RECEPTOR-BLOCKING AGENT AND TRYPTOPHANE | CIBA-GEIGY CORPORATION (US) | 1979-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10828281-B2 | Non-hydrophobic compounds for use in treating metastasis and/or cartilage defect | VIM, MATR3, TP53 | MAPT 168/4885ADRB2 4055/4885ADRB1 4181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.